Belinostat loaded lipid–polymer hybrid nanoparticulate delivery system for breast cancer: improved pharmacokinetics and biodistribution in a tumor model

Pradyuth, Kommera Sai; Salunkhe, Shubham A.; Singh, Arihant Kumar; Chitkara, Deepak; Mittal, Anupama

doi:10.1039/d3tb01317k

J. Mater. Chem. B

2023

DOI: 10.1039/d3tb01317k

|View full text |Cite

Belinostat loaded lipid–polymer hybrid nanoparticulate delivery system for breast cancer: improved pharmacokinetics and biodistribution in a tumor model

Kommera Sai Pradyuth,

Shubham A. Salunkhe,

Arihant Kumar Singh

et al.

Abstract: Despite various treatment modalities for breast cancer, it still persists as one of the most diagnosed types of cancer in females. The recent investigations in epigenetics of breast cancer reveal...

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 6 publications

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Targeting the epigenome with advanced delivery strategies for epigenetic modulators

Guha,

Jagadeesan,

Pandey

et al. 2024

Bioengineering & Transla Med

View full text Add to dashboard Cite

Epigenetics mechanisms play a significant role in human diseases by altering DNA methylation status, chromatin structure, and/or modifying histone proteins. By modulating the epigenetic status, the expression of genes can be regulated without any change in the DNA sequence itself. Epigenetic drugs exhibit promising therapeutic efficacy against several epigenetically originated diseases including several cancers, neurodegenerative diseases, metabolic disorders, cardiovascular disorders, and so forth. Currently, a considerable amount of research is focused on discovering new drug molecules to combat the existing research gap in epigenetic drug therapy. A novel and efficient delivery system can be established as a promising approach to overcome the drawbacks associated with the current epigenetic modulators. Therefore, formulating the existing epigenetic drugs with distinct encapsulation strategies in nanocarriers, including solid lipid nanoparticles, nanogels, bio‐engineered nanocarriers, liposomes, surface modified nanoparticles, and polymer–drug conjugates have been examined for therapeutic efficacy. Nonetheless, several epigenetic modulators are untouched for their therapeutic potential through different delivery strategies. This review provides a comprehensive up to date discussion on the research findings of various epigenetics mechanism, epigenetic modulators, and delivery strategies utilized to improve their therapeutic outcome. Furthermore, this review also highlights the recently emerged CRISPR tool for epigenome editing.

show abstract

Targeting the epigenome with advanced delivery strategies for epigenetic modulators

Guha,

Jagadeesan,

Pandey

et al. 2024

Bioengineering & Transla Med

View full text Add to dashboard Cite

show abstract

A Simple Method for the Preparation and Characterization of Nanostructured Lipid Carriers (NLC) Formulations for Cutaneous Use

Silva,

Loureiro

2024

J. Chem. Educ.

View full text Add to dashboard Cite

PXD101 inhibits malignant progression and radioresistance of glioblastoma by upregulating GADD45A

Hu,

Zhou,

Peng

et al. 2024

J Transl Med

View full text Add to dashboard Cite

Histone deacetylase inhibitors (HDACis) have shown a significant antitumor effect in clinical studies, and PXD101 is a novel HDACi which can cross the blood-brain barrier. In this study, we showed that PXD101 could significantly inhibit the proliferation and invasion of glioblastoma (GBM) cells, while promoting their apoptosis and radiosensitivity. Furthermore, it was found that PXD101 exerted its antitumor function by upregulating the expression of the growth arrest and DNA damage inducible protein α (GADD45A). Mechanistically, PXD101 promoted the transcription of GADD45A by directly acetylating the histones H3 and H4, and GADD45A enhanced apoptosis and radiosensitivity through the activation of P38 in the GBM cells. In vivo experiments also showed that PXD101 combined with radiotherapy could significantly inhibit the growth of GBM. This study provides experimental evidence for application of the novel HDACi PXD101 in the treatment of GBM, as well as new molecular markers and potential intervention targets that may be used in preventing GBM malignant progression and radioresistance.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Belinostat loaded lipid–polymer hybrid nanoparticulate delivery system for breast cancer: improved pharmacokinetics and biodistribution in a tumor model

Abstract: Despite various treatment modalities for breast cancer, it still persists as one of the most diagnosed types of cancer in females. The recent investigations in epigenetics of breast cancer reveal...

Cited by 6 publications

References 56 publications

Targeting the epigenome with advanced delivery strategies for epigenetic modulators

Targeting the epigenome with advanced delivery strategies for epigenetic modulators

A Simple Method for the Preparation and Characterization of Nanostructured Lipid Carriers (NLC) Formulations for Cutaneous Use

PXD101 inhibits malignant progression and radioresistance of glioblastoma by upregulating GADD45A

Contact Info

Product

Resources

About